GRAIL, LLC

Galleri Test

Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.

We are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges.

GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. 

For more information, please visit grail.com.

Community Guidelines: https://bit.ly/3xigb24 

6 Dimensions Capital

Ally Bridge Group

Sequoia Capital China

Blue Pool Capital

Genuity Science

Hillhouse Capital Group

China Merchants Securities

Canada Pension Plan Investment Board

Huangpu River Capital

PSP Investments

Illumina

GRAIL

GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. 

This accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu

This week GRAILers gathered to celebrate the upcoming #LunarNewYear. Best wishes and good fortune to all in the Year of the Dragon! 
#DiversityAndInclusion  

From addressing health disparities to advancing the science of cancer genomics, multi-cancer early detection has implications for many aspects of #cancer screening and care. We’re exploring the impacts of this technology on our podcast, The Cancer SIGNAL.

Subscribe here for new monthly episodes: https://bit.ly/42x1y9v

We’re excited to announce the name change of BIG (Black & Brown Influencers at GRAIL) in time for #BlackHistoryMonth! Anwell Wilbekin and Rich S.T Gilliam, co-leaders of BIG, unveil the new identity and outline upcoming events. We've curated insightful panel discussions on influence and health equity, along with a creative virtual paint night. Stay tuned for a month filled with celebration and empowerment at GRAIL! #DiversityAndInclusion #GRAILproud 

Proactive tools, like multi-cancer early detection tests, are helping people take more control of their health – but there’s more work to be done to help #CloseTheCareGap.

Ahead of #WorldCancerDay, we’re revisiting our podcast interview with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum, as he discusses how we can address barriers to equity in cancer screening. Hear more in this episode of #TheCancerSignal: https://bit.ly/49eqd5z 

Find us on all major podcast platforms:  
Apple: https://apple.co/3W0dso3  
Spotify: https://spoti.fi/3Kbe9Z8 
Google: https://bit.ly/3Fmp9j4 

	Dec '21	Dec '22	Dec '23
net income	-1.25B -	-5.40B 332.70%	-1.47B 72.85%
depreciation and amortization	58.45M -	154.76M 164.78%	158.70M 2.54%
deferred income tax	-17.48M -	-39.06M 123.51%	-38.15M 2.33%
stock based compensation	681.91M -	34.72M 94.91%	20.32M 41.46%
change in working capital	21.59M -	-14.46M 167.00%	7.72M 153.38%
accounts receivables	-6.88M -	-8.68M 26.05%	-1.38M 84.06%
inventory	-5.67M -	-14.08M 148.23%	-1.94M 86.22%
accounts payables	1.30M -	2.34M 80.42%	2.89M 23.46%
other working capital	32.85M -	5.95M 81.87%	8.15M 36.97%
other non cash items	625.24M -	5.07B 710.32%	1.06B 79.09%
net cash provided by operating activities	-688.13M -	-561.31M 18.43%	-595.80M 6.14%
investments in property plant and equipment	-69.93M -	-22.86M 67.31%	-12.89M 43.62%
acquisitions net
purchases of investments	-159.41M -
sales maturities of investments	574.15M -
other investing activites	414.74M -
net cash used for investing activites	344.81M -	-22.86M 106.63%	-12.89M 43.62%
debt repayment
common stock issued	5.98M -
common stock repurchased	-170K -	-4.18M 2,360.59%	-234K 94.41%
dividends paid
other financing activites	388.93M -	604.82M 55.51%	463.77M 23.32%
net cash used provided by financing activities	394.74M -	604.82M 53.22%	463.77M 23.32%
effect of forex changes on cash	-199K -	-511K 156.78%	305K 159.69%
net change in cash	658.85M -	15.60M 97.63%	-144.31M 1,024.94%
cash at beginning of period	143.19M -	225.99M 57.83%	241.60M 6.90%
cash at end of period	802.04M -	241.60M 69.88%	97.29M 59.73%
operating cash flow	-688.13M -	-561.31M 18.43%	-595.80M 6.14%
capital expenditure	-69.93M -	-22.86M 67.31%	-12.89M 43.62%
free cash flow	-758.06M -	-584.17M 22.94%	-608.69M 4.20%

GRAL

COM:GRAIL

GRAIL

Last Close

16.38

22/11 21:00

Market Cap

431.58M

Beta: -

Volume Today

526.34K

Avg: -

Preview